Notes d’analyste

09/01/2026 Edison : Renewed focus on advancing core assets

09/12/2025 Kepler Cheuvreux : OSE Immunotherapeutics unveils its 26-28 strategic plan

09/12/2025 Edison : Strategic plan presented for 2026-2028

09/12/2025 All invest Securities: L'heure de l'action

20/10/2025 Edison : Refocusing for the next phase

06/10/2025 All invest Securities : RETOUR DE VISIBILITÉ, LE PLAN DE MARCHE EST LANCÉ

12/09/2025 All invest Securities : L'heure de l'action

12/09/2025 Kepler Cheuvreux : Completes the patient recruitment for the Combi-TED P2 study

29/08/2025 Edison: Spotlight on OSE's diverse clinical pipeline

18/06/2025 All invest Securities : AG SUR FOND DE TENSIONS : DIVERGENCE STRATÉGIQUE À L’ODJ

05/06/2025 Edison: New UC biomarker underpins growth strategy

03/06/2025 Edison : ASCO 2025 update showcases Tedopi potential

03/06/2025 Kepler Cheuvreux : OSE Immunotherapeutics Provides additional data about TEDOPaM study at ASCO25

22/05/2025 Kepler Cheuvreux: OSE Immunotherapeutics strenghtens mRNA capabilities through new public-private consortium

22/05/2025 Edison: Strategic collaboration in mRNA technologies

06/05/2025 Edison : Lusvertikimab impresses in extension period data

06/05/2025 All invest Securities : + DE 90% DE RÉPONDEURS EN PHASE DE MAINTENANCE

03/04/2025 Edison: Primed for value appreciation

1 2 3 4